Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Seoul Semiconductor’s SunLike Series Natural Spectrum LEDs Shown in a Recent Study to Have Beneficial Effects on Human Health and Well-being

Published

on

Reading Time: 4 minutes

MUNICH, Germany–(BUSINESS WIRE)–Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global
innovator of LED products and technology, announced the results of a
recent study conducted by Dr. Octavio L. Perez, adjunct researcher in
Integrative Lighting at Mount Sinai Hospital in NYC, NY, USA on the
non-visual melanopic stimulus of LED sources. The study showed that the
company’s SunLike Series natural spectrum LEDs provide up to 21% more
melanopic stimulus than conventional LEDs at 4000K, and the same
melanopic stimulus as daylight at 6500K (D65).

In addition to the visual effects of light and lighting on people, such
as visual acuity and color fidelity, there are also non-visual effects.
These non-visual effects can affect human health and well-being in
aspects related to sleep, awakeness, alertness, circadian rhythmicity,
circadian disruption, performance, and mood. Recent building standards,
such as the ‘WELL
Building Standard
,’ assess these non-visual effects of lighting in
buildings in terms of the ‘melanopic stimulus,’ not just in terms of
conventional photometry and colorimetry.

The recent study evaluated the M-EDI (CIE DIS S026/E:2018 Melanopic
Equivalent Daylight Illuminance) of different light sources at different
correlated color temperatures (CCT in K). M-EDI is the only metric
compliant with the International System of Units (IS) to evaluate the
non-visual stimulus of light and lighting, based on the CIE (the
International Commission on Illumination) D65 standard daylight
illuminant. The preliminary results indicate that the SunLike Series
natural spectrum LEDs provide more melanopic stimulus, at any given CCT,
than any other LED light source at the same photopic illuminance (in
lux) – up to 21% more M-EDI stimulus compared to a conventional 4000K
CRI80 LED (4000K being the prevalent CCT in office and school
environments).

A typical 4000K CRI80 LED provides 59.30 M-EDI lux for every 100
photopic lux, and a 4000K SunLike LED provides 71.94 M-EDI lux at the
same photopic illuminance level. At 6500K, the SunLike LED delivers
99.95% of the M-EDI melanopic stimulus provided by the CIE D65 daylight
standard illuminant at the same photopic illuminance. It means that at
6500K, the SunLike Series LEDs provide the same natural melanopic
stimulus as daylight (D65).

Advertisement
Stake.com

The reason for this is that the SunLike Series natural spectrum LEDs
have a continuous spectral power distribution (SPD) emission that mimics
sunlight spectrum at different CCT, in the visual region not including
UV and IR. Conventional LED light sources have a peak at 450nm, followed
by a valley at the peak of the melanopic efficiency curve, around 480nm.
This peak at 450nm for conventional LEDs may also produce non-desired
effects on eye health. The melanopic stimulus of the 6500K SunLike LEDs
match the shape of the melanopic stimulus provided by D65, avoiding
potential blue light peak and ethical issues.

Human centric lighting solutions go beyond the prevalent visual metrics
of photometry colorimetry and conventional lighting design. The SunLike
Series natural spectrum LEDs offer better visual appearance and color
fidelity (CRI95+), and are specifically designed and engineered to
provide more benefits and energy for human health and well-being than
any other LED in the marketplace. SunLike Series LEDs are the light
source of choice for integrative lighting solutions.

Seoul Semiconductor’s SunLike Series natural spectrum LEDs are the
world’s first LEDs to produce light that closely matches the spectrum of
natural sunlight. It has also achieved the highest level of eye safety
certification from the International Commission on Illumination as an
RG-1 level light source with no photo-biological risks.

SunLike Series natural spectrum LEDs were co-developed through the
combination of Seoul Semiconductor’s optical semiconductor technology
and Toshiba Materials’ TRI-R technology, which defines its original
concept as “the light closest to the sun for human well-being.” TRI-R
technology enables the spectrum of natural sunlight to be reproduced by
a white LED light source. TRI-R is a registered trademark of Toshiba
Material Co., Ltd.

The left figure is how the melanopic stimulus of commercial LEDs
increases and the right figure shows the same results by family of LEDs.
SunLike LEDs provide more melanopic stimulus than the other LEDs (study
under publication).

Advertisement
Stake.com

# # #

About Dr. Octavio L. Perez
Dr. Octavio L. Perez is a
passionate professional and scholar who contributes to exploring,
developing and bringing to the real world the benefits of light and
lighting for human wellbeing and wellness, and ultimately health,
integrating in this vision the traditional visual and aesthetical
principles of lighting, altogether with energy savings and
sustainability values. He works internationally as an independent
consultant, focused in human centric lighting (HCL), more precisely
“affective lighting”. He is also an adjunct researcher at Mount Sinai
Hospital in NYC, where he completed his doctoral research with funding
from NIH (National Institutes of Health).

About Seoul Semiconductor
Seoul Semiconductor develops and
commercializes LEDs for automotive, general illumination, specialty
lighting, and backlighting markets. As the second-largest LED
manufacturer globally excluding the captive market, Seoul Semiconductor
holds more than 14,000 patents, offers a wide range of technologies, and
mass produces innovative LED products such as SunLike – delivering the
world’s best light quality in a next-generation LED enabling
human-centric lighting optimized for circadian rhythms; WICOP – a
simpler structured package-free LED which provides market leading color
uniformity and cost savings at the fixture level, providing high lumen
density and design flexibility; NanoDriver Series – the world’s smallest
24W DC LED drivers; Acrich, the world’s first high-voltage AC-driven LED
technology developed in 2005, including all AC LED-related technologies
from chip to module and circuit fabrication, and nPola, a new LED
product based on GaN-substrate technology that achieves more than ten
times the output of conventional LEDs. UCD constitutes a high color
gamut display which delivers more than 90% NTSC. For more information,
please visit www.seoulsemicon.com/en.

Contacts

Advertisement
Stake.com

Seoul Semiconductor Inc.
Jeonghee Kim
Tel:
+82-70-4391-8311
Email: [email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Rodedawg (OTC: RWGI) Launches TikTok Shop to Expand into Global E-Commerce Market

Published

on

Continue Reading

Billion

Industrial Hemp Market Soars from $6.6 Billion to $25.7 Billion by 2034, Fueled by Sustainable Innovation

Published

on

industrial-hemp-market-soars-from-$66-billion-to-$25.7-billion-by-2034,-fueled-by-sustainable-innovation

Industrial Hemp Playing Key Role in Carbon Sequestration and Soil Remediation Aligning with Sustainable Farming Practices

ROCKVILLE, Md., June 12, 2024 /PRNewswire/ — Based on a new research report by Fact.MR, worldwide sales of Industrial Hemp Market are estimated to reach US$ 6.6 billion in 2024. By 2034, this market is anticipated to skyrocket to a staggering US$ 25.7 billion, driven by a steady CAGR of 14.5% from 2024 onward.

Demand for industrial hemp is skyrocketing as more and more industries recognize its versatile and sustainable properties. Once overlooked, this remarkable crop is now being embraced for its myriad uses across various sectors. From textiles and construction materials to biofuels and nutritional supplements, hemp’s applications are seemingly endless.

Environmentally conscious consumers are driving much of this demand, as hemp requires minimal pesticides and herbicides, making it an eco-friendly choice for sustainable farming. Its ability to sequester carbon dioxide and remediate contaminated soil further adds to its appeal. Moreover, hemp’s durability, lightweight nature, and renewable qualities make it an attractive alternative to traditional materials in manufacturing.

Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=3989

Advertisement
Stake.com

As awareness of hemp’s benefits continues to spread, industries are investing in research and development to unlock its full potential. With its multi-faceted applications and sustainable credentials, industrial hemp is poised to become a cornerstone of the green economy, meeting the growing demand for environmentally responsible products and practices.

Key Takeaways from the Market Study:

  • Based on nature, sales of organic hemp are estimated to reach a valuation of $3.2 billion in 2024.
  • The market in Mexico is evaluated to expand at a CAGR of 13.6% from 2024 to 2034.
  • Revenue from sales of industrial hemp in East Asia is projected to reach $5.9 billion by the end of 2034.
  • The South Korean market is evaluated to reach a valuation of $1.4 billion by the end of 2034.
  • North America is analyzed to hold a global market share of 24.3% by 2034.

“Use of industrial hemp in textiles, medicines, and food, coupled with global sustainability trends, is creating opportunities for suppliers. Governments worldwide are collaborating to boost global hemp distribution,” says a Fact.MR analyst.

Increasing Awareness of Therapeutic Potential of Hemp in Medical Applications

Once relegated to the fringes, industrial hemp is rapidly emerging as a sustainable wonder crop, fueling a wave of cutting-edge innovations across diverse industries. As researchers and entrepreneurs unlock its vast potential, hemp is proving to be a versatile and eco-friendly resource, paving the way for exciting new products and applications.

The automotive industry is also exploring the use of hemp fibers as a reinforcement material for lighter, stronger, and more sustainable car parts. These natural fiber composites could reduce vehicle weight, improving fuel efficiency and reducing emissions.

Advertisement
Stake.com

In the field of biotechnology, scientists are harnessing the unique properties of hemp to develop innovative products. For instance, researchers are exploring the use of hemp-derived compounds, such as cannabidiol (CBD), for their potential therapeutic applications in various medical conditions.

Japan’s Industrial Hemp Market Poised for Rapid Growth

The industrial hemp market in Japan is projected to grow at a compound annual growth rate (CAGR) of 15.1% from 2024 to 2034, with the country expected to hold a 29.4% market share by the end of the period.

Increased investment in research is crucial for unlocking the full potential of industrial hemp. Research efforts may focus on improving hemp genetics for higher yield and quality, optimizing cultivation practices, and exploring innovative applications such as advanced nanomaterials or pharmaceuticals. This investment fosters innovation and establishes a foundation for the hemp industry’s long-term growth and competitiveness in an ever-evolving market.

Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=3989

Advertisement
Stake.com

Expanding Opportunities in the United States Industrial Hemp Market

The industrial hemp market in the United States offers abundant opportunities for stakeholders to broaden their product portfolios. Beyond traditional uses like textiles and oils, there is significant potential for hemp-based products to evolve into biodegradable polymers, eco-friendly packaging, and even biofuels. This diversification, a prominent trend in the industrial hemp market, not only targets emerging markets but also positions hemp as a versatile and sustainable resource with applications across various industries.

More Valuable Insights on Offer:

Fact.MR, in its new offering, presents an unbiased analysis of the industrial hemp market for 2019 to 2023 and forecast statistics for 2024 to 2034.

The study divulges essential insights into the market based on nature (organic, conventional), product type (fiber, seeds), and end use (food & beverages, consumer textiles, personal products, industrial applications, hemp CBD, supplements, other consumer products), across seven major regions of the world (North America, Latin America, Eastern Europe, Western Europe, East Asia, South Asia & Pacific, and MEA).

Advertisement
Stake.com

Check out More Related Studies Published by Fact.MR Research:

Hemp-Based Products Market is expected to reach $1.8 billion in 2023 and jump to a size of $16.2 billion by 2033.

Cannabis Infused Drinks Market is predicted to race ahead and end up at US$ 8.7 billion by 2032.

Ready-to-use Therapeutic Food Market to surge from $459.9M in 2024 to $800.6M by 2034, driven by 5.7% CAGR, marking substantial growth.

Specialty Fat and Oil Market will hit $85.94 billion by 2034 with a 4.6% Annual Growth Rate.

Advertisement
Stake.com

Baking Ingredient Market is set to reach $41.48 billion by 2034, Driven by 6.5% Annual Growth Rate.

Infant Milk Formula Market: From Growth Spurts to Baby Boom – Projected Surge to $22.35 Billion by 2034.

About Us:

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape. 

Advertisement
Stake.com

Contact:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Sales Team[email protected]
Follow Us: LinkedIn | Twitter | Blog

 

View original content:https://www.prnewswire.co.uk/news-releases/industrial-hemp-market-soars-from-6-6-billion-to-25-7-billion-by-2034–fueled-by-sustainable-innovation-302170602.html

Continue Reading

Innocan

Innocan Pharma Announces Successful Preliminary Safety Evaluation of LPT-CBD in Minipigs

Published

on

innocan-pharma-announces-successful-preliminary-safety-evaluation-of-lpt-cbd-in-minipigs

HERZLIYA, Israel and CALGARY, AB, June 11, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the success and conclusion of a preliminary safety evaluation of Innocan’s single injection and sustained-release LPT-CBD conducted on minipigs. The animals demonstrated excellent drug tolerance and did not exhibit any drug-related adverse events.

 

 

Recognized by the FDA as an excellent model for toxicology, small breeds of miniature domestic pigs known as minipigs share strong similarities with humans in crucial aspects such as drug metabolism, skin structure, genetics, and physiological mechanisms. In this preliminary safety study, minipigs received a single subcutaneous injection of LPT-CBD and were closely monitored for pharmacokinetics and basic safety parameters over one month. Encouragingly, the animals all exhibited good drug tolerance and did not manifest any drug-related adverse reactions.

“We are thrilled with these findings, which further underpin the safety profile of LPT-CBD following a single injection,” commented Dr. Eyal Kalo, the R&D Director of Innocan Pharma. “With each new data point collected for LPT-CBD, we make significant strides in our quest to revolutionize patient care through sustained-release therapy. Our efforts to continuously gather data to fully characterize LPT-CBD are paramount in our journey towards its ultimate approval.”

Advertisement
Stake.com

Professor Chezy Barenholz the CSO of Innocan Pharma added, “These results are immensely gratifying and hold significant promise as they highlight the characteristics of LPT-CBD in a physiological setting similar to humans.”

The study involved administering three ascending doses of LPT-CBD via subcutaneous injection in minipigs, followed by comprehensive monitoring of pharmacokinetics and safety parameters for 28 days. Throughout the study, the minipigs demonstrated excellent drug tolerance, as evidenced by blood clinical parameters whithin normal range, healthy appetite, and normal behavior. These findings are consistent with prior safety evaluations conducted with LPT-CBD on diverse animal models including goats and dogs, affirming the drug’s favorable tolerability profile following both single and repeated use.

Grant of Restricted Share Units                                                                                                 

The Company has granted an aggregate of 290,000 restricted share units (each, an “RSU“) to consultants. Each RSU entitles the recipient to receive one common share of the Company (a “Common Share“) on vesting. A total of 150,000 RSUs vest on May 30, 2024, and 140,000 RSUs vest on September 30, 2024. The RSUs and the underlying Common Shares are subject to a statutory hold period of four months and one day expiring on October 1, 2024.

Innocan also announces that it granted 2,380,000 stock options to employees and consultants to the Company. These options have a strike price of $0.28, with various vesting periods up to 12 months. All options expire on May 30, 2029.

Advertisement
Stake.com

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected] 

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Advertisement
Stake.com

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Advertisement
Stake.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-successful-preliminary-safety-evaluation-of-lpt-cbd-in-minipigs-302169232.html

Continue Reading
Advertisement
Stake.com

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania